MicroRNA-122 in patients with hepatitis B and hepatitis B virus-associated hepatocellular carcinoma
Author(s) -
MohammadReza MahmoudianSani,
Samira Asgharzade,
Arash Alghasi,
Ali Saeedi-Boroujeni,
Seyed Jafar Adnani Sadati,
Mohammad-Taghi Moradi
Publication year - 2019
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo.2019.02.14
Subject(s) - microrna , mir 122 , medicine , hepatocellular carcinoma , pathogenesis , hepatitis b virus , disease , biomarker , immunology , virus , liver disease , virology , hepatitis b , pathology , hepatitis c virus , cancer research , gene , biology , genetics
Hepatitis B virus (HBV) infection is known as a serious problem in the domain of public health and approximately 350 million people across the world are affected with this infectious disease. As well, microRNAs are recognized as a type of small non-coding RNAs that can be widely used as a diagnostic biomarker and prognosis method of special diseases. In this respect, microRNA-122 or miR-122 can play a significant role in the pathogenesis of several hepatic diseases. Given the importance of microRNA-122 in the liver as well as its pathology, this study focused on the potential functions of microRNA-122 in pathogenesis, diagnosis, and treatment of HBV infection. In this regard, the findings of previous studies had indicated that expression of microRNA-122 in patients with HBV infection could be significantly deregulated. The results of this study were consistent with the idea that diagnosis and treatment of this infectious disease using microRNA-122 could be an efficient method.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom